Highlights
- 1
- 2Journal of managed care & specialty pharmacy · 2020
- 3Journal of clinical gastroenterology · 2023
Publications
93 publications
Funding
1 grant
Completed grants (1)
- Sub-PISIRF 170048-01A Pilot Study to Correlate Changes in Gastrointestinal Motility, Microbiome Composition, and GI Symptomatology with Transjugular Intraheptic Portosystemic Shunt (TIPS) Creation in Cirrhotics With PortSociety of Interventional Radiology Foundation · 2016–2019 · via New York University School of Medicine (Grossman)
Clinical research
8 studies
Completed & closed trials (8)
- PINCT03973372Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the Management of Portal Hypertension - A 5-year Longitudinal Observational Study of Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) PlacementNorthwestern University · CLOSED TO ACCRUAL (as of 2024)Cirrhosis, Liver; Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- PINCT05071716A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisPHASE3 · Salix Pharamaceuticals, Inc. · IRB STUDY CLOSURE (as of 2024)Hepatic Encephalopathy
- PINCT05281328A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver DiseasePHASE2; PHASE3 · Camurus AB · CLOSED TO ACCRUAL (as of 2024)Polycystic Liver Disease
- PITreatment of Single Patient Infected with Hepatitis D Virus Infection Using Bulveritide.Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2024)
- PIBleeding in Hospitalized Patients with Liver Disease Undergoing Procedures (PROC-BLeeD Follow-up)University of Virginia · IRB STUDY CLOSURE (as of 2023)
- PICirrhosis Quality Collaborative (CQC): A Collaborative Care Network for Adult Cirrhosis.Loma Linda University · IRB STUDY CLOSURE (as of 2023)
- PINCT04874350A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and SarcopeniaPHASE2 · Lipocine Inc. · IRB STUDY CLOSURE (as of 2022)Liver Cirrhosis; Sarcopenia
- PINCT04816916A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)PHASE2 · Axcella Health Inc. · IRB STUDY CLOSURE (as of 2022)Hepatic Encephalopathy
News mentions
2 mentionsView all WCM news ↗
- Many Americans Lack Access to a GastroenterologistFebruary 6, 2025
Almost 50 million Americans—disproportionately in rural areas—must drive 25 miles or more to access a gastroenterologist for diagnosis and treatment of issues involving the digestive system, according to a study from Weill Cornell Medicine researchers.
- Maximizing Healthcare Resources: Generic Hepatitis B Drugs Cut Costs, Enhanced AccessJuly 24, 2023
The availability of generic antiviral drugs to manage chronic hepatitis B resulted in significant savings to Medicare, despite an increase in prescriptions, according to an analysis by researchers at Weill Cornell Medicine and NewYork-Presbyterian.
Media highlights
1 clip
- Recent Developments May Change Care Landscape In Hepatitis BHealio · October 29, 2026
External relationships
Other
Becton Dickinson and Company · Empire Liver Foundation, LLC · Madrigal Pharmaceuticals, Inc. · Mallinckrodt, Inc. · Novo Nordisk Pharmaceuticals, Inc. · Salix Pharamaceuticals, Inc.